Compare Adaptive Biotechnologies Corp (ADPT) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Select Medical Holdings Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SEM | |
|---|---|---|
Market Cap | $3.33B | $2.05B |
Sector | Health | Health |
52-Week High | $22.37 | $16.66 |
52-Week Low | $10.24 | $11.77 |
Enterprise Value | $3.19B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, with a bullish technical signal supported by oversold RSI readings. The company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43 and P/S of 0.36 indicating reasonable valuation. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share, finalized on June 30, 2026.
The acquisition at $16.50 per share, just below the current price, limits near-term upside, while ongoing legal investigations into the board's fiduciary duties pose governance risks. Analyst consensus is mixed with 35.71% buy ratings, but stagnant revenue and declining net income margins signal fundamental challenges. Investors should weigh the acquisition's finality against operational headwinds and shareholder litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
